0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Primary Immunodeficiency Drug Market Research Report 2024
Published Date: July 2024
|
Report Code: QYRE-Auto-10Q15349
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Primary Immunodeficiency Drug Market Research Report 2023
BUY CHAPTERS

Global Primary Immunodeficiency Drug Market Research Report 2024

Code: QYRE-Auto-10Q15349
Report
July 2024
Pages:95
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Primary Immunodeficiency Drug Market Size

The global Primary Immunodeficiency Drug market was valued at US$ 6820 million in 2023 and is anticipated to reach US$ 10690 million by 2030, witnessing a CAGR of 6.5% during the forecast period 2024-2030.

Primary Immunodeficiency Drug Market

Primary Immunodeficiency Drug Market

Drugs for the treatment of primary immunodeficiency diseases
Based on disease or condition, the antibody deficiency segment held the largest share in the overall PIDD market owing to the increasing number of patients diagnosed with common variable immunodeficiency and selective IgA deficiency. In terms of treatment methods, immunoglobulin replacement therapy occupies the largest share of the global PID market, and is an effective, safe and preferred therapy for the treatment of primary immunodeficiency.
This report aims to provide a comprehensive presentation of the global market for Primary Immunodeficiency Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Immunodeficiency Drug.

Report Scope

The Primary Immunodeficiency Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Primary Immunodeficiency Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Immunodeficiency Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Primary Immunodeficiency Drug Market Report

Report Metric Details
Report Name Primary Immunodeficiency Drug Market
Accounted market size in 2023 US$ 6820 million
Forecasted market size in 2030 US$ 10690 million
CAGR 6.5%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • Immunoglobulin
  • Antibiotic
  • Stem Cell
  • Other
Segment by Application
  • Antibody Deficiency
  • Cellular Immunodeficiency
  • Innate Immune Disease
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company ADMA Biologics, Inc., CSL Behring, LLC, Octapharma, Takeda Pharmaceutical Company, Grifols Biologicals, Inc., Baxter, Kedrion Biopharma, BPL Inc., Pharming Group, Shire, Chengdu Rongsheng Pharmaceutical Co., Ltd
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Primary Immunodeficiency Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Primary Immunodeficiency Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Primary Immunodeficiency Drug Market growing?

Ans: The Primary Immunodeficiency Drug Market witnessing a CAGR of 6.5% during the forecast period 2024-2030.

What is the Primary Immunodeficiency Drug Market size in 2030?

Ans: The Primary Immunodeficiency Drug Market size in 2030 will be US$ 10690 million.

Who are the main players in the Primary Immunodeficiency Drug Market report?

Ans: The main players in the Primary Immunodeficiency Drug Market are ADMA Biologics, Inc., CSL Behring, LLC, Octapharma, Takeda Pharmaceutical Company, Grifols Biologicals, Inc., Baxter, Kedrion Biopharma, BPL Inc., Pharming Group, Shire, Chengdu Rongsheng Pharmaceutical Co., Ltd

What are the Application segmentation covered in the Primary Immunodeficiency Drug Market report?

Ans: The Applications covered in the Primary Immunodeficiency Drug Market report are Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disease, Other

What are the Type segmentation covered in the Primary Immunodeficiency Drug Market report?

Ans: The Types covered in the Primary Immunodeficiency Drug Market report are Immunoglobulin, Antibiotic, Stem Cell, Other

1 Primary Immunodeficiency Drug Market Overview
1.1 Product Overview and Scope of Primary Immunodeficiency Drug
1.2 Primary Immunodeficiency Drug Segment by Type
1.2.1 Global Primary Immunodeficiency Drug Market Value Comparison by Type (2024-2030)
1.2.2 Immunoglobulin
1.2.3 Antibiotic
1.2.4 Stem Cell
1.2.5 Other
1.3 Primary Immunodeficiency Drug Segment by Application
1.3.1 Global Primary Immunodeficiency Drug Market Value by Application: (2024-2030)
1.3.2 Antibody Deficiency
1.3.3 Cellular Immunodeficiency
1.3.4 Innate Immune Disease
1.3.5 Other
1.4 Global Primary Immunodeficiency Drug Market Size Estimates and Forecasts
1.4.1 Global Primary Immunodeficiency Drug Revenue 2019-2030
1.4.2 Global Primary Immunodeficiency Drug Sales 2019-2030
1.4.3 Global Primary Immunodeficiency Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Primary Immunodeficiency Drug Market Competition by Manufacturers
2.1 Global Primary Immunodeficiency Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Primary Immunodeficiency Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Primary Immunodeficiency Drug Average Price by Manufacturers (2019-2024)
2.4 Global Primary Immunodeficiency Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Primary Immunodeficiency Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Primary Immunodeficiency Drug, Product Type & Application
2.7 Primary Immunodeficiency Drug Market Competitive Situation and Trends
2.7.1 Primary Immunodeficiency Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Primary Immunodeficiency Drug Players Market Share by Revenue
2.7.3 Global Primary Immunodeficiency Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Primary Immunodeficiency Drug Retrospective Market Scenario by Region
3.1 Global Primary Immunodeficiency Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Primary Immunodeficiency Drug Global Primary Immunodeficiency Drug Sales by Region: 2019-2030
3.2.1 Global Primary Immunodeficiency Drug Sales by Region: 2019-2024
3.2.2 Global Primary Immunodeficiency Drug Sales by Region: 2025-2030
3.3 Global Primary Immunodeficiency Drug Global Primary Immunodeficiency Drug Revenue by Region: 2019-2030
3.3.1 Global Primary Immunodeficiency Drug Revenue by Region: 2019-2024
3.3.2 Global Primary Immunodeficiency Drug Revenue by Region: 2025-2030
3.4 North America Primary Immunodeficiency Drug Market Facts & Figures by Country
3.4.1 North America Primary Immunodeficiency Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Primary Immunodeficiency Drug Sales by Country (2019-2030)
3.4.3 North America Primary Immunodeficiency Drug Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Primary Immunodeficiency Drug Market Facts & Figures by Country
3.5.1 Europe Primary Immunodeficiency Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Primary Immunodeficiency Drug Sales by Country (2019-2030)
3.5.3 Europe Primary Immunodeficiency Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Primary Immunodeficiency Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Primary Immunodeficiency Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Primary Immunodeficiency Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Primary Immunodeficiency Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Primary Immunodeficiency Drug Market Facts & Figures by Country
3.7.1 Latin America Primary Immunodeficiency Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Primary Immunodeficiency Drug Sales by Country (2019-2030)
3.7.3 Latin America Primary Immunodeficiency Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Primary Immunodeficiency Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Primary Immunodeficiency Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Primary Immunodeficiency Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Primary Immunodeficiency Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Primary Immunodeficiency Drug Sales by Type (2019-2030)
4.1.1 Global Primary Immunodeficiency Drug Sales by Type (2019-2024)
4.1.2 Global Primary Immunodeficiency Drug Sales by Type (2025-2030)
4.1.3 Global Primary Immunodeficiency Drug Sales Market Share by Type (2019-2030)
4.2 Global Primary Immunodeficiency Drug Revenue by Type (2019-2030)
4.2.1 Global Primary Immunodeficiency Drug Revenue by Type (2019-2024)
4.2.2 Global Primary Immunodeficiency Drug Revenue by Type (2025-2030)
4.2.3 Global Primary Immunodeficiency Drug Revenue Market Share by Type (2019-2030)
4.3 Global Primary Immunodeficiency Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Primary Immunodeficiency Drug Sales by Application (2019-2030)
5.1.1 Global Primary Immunodeficiency Drug Sales by Application (2019-2024)
5.1.2 Global Primary Immunodeficiency Drug Sales by Application (2025-2030)
5.1.3 Global Primary Immunodeficiency Drug Sales Market Share by Application (2019-2030)
5.2 Global Primary Immunodeficiency Drug Revenue by Application (2019-2030)
5.2.1 Global Primary Immunodeficiency Drug Revenue by Application (2019-2024)
5.2.2 Global Primary Immunodeficiency Drug Revenue by Application (2025-2030)
5.2.3 Global Primary Immunodeficiency Drug Revenue Market Share by Application (2019-2030)
5.3 Global Primary Immunodeficiency Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 ADMA Biologics, Inc.
6.1.1 ADMA Biologics, Inc. Corporation Information
6.1.2 ADMA Biologics, Inc. Description and Business Overview
6.1.3 ADMA Biologics, Inc. Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 ADMA Biologics, Inc. Primary Immunodeficiency Drug Product Portfolio
6.1.5 ADMA Biologics, Inc. Recent Developments/Updates
6.2 CSL Behring, LLC
6.2.1 CSL Behring, LLC Corporation Information
6.2.2 CSL Behring, LLC Description and Business Overview
6.2.3 CSL Behring, LLC Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 CSL Behring, LLC Primary Immunodeficiency Drug Product Portfolio
6.2.5 CSL Behring, LLC Recent Developments/Updates
6.3 Octapharma
6.3.1 Octapharma Corporation Information
6.3.2 Octapharma Description and Business Overview
6.3.3 Octapharma Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Octapharma Primary Immunodeficiency Drug Product Portfolio
6.3.5 Octapharma Recent Developments/Updates
6.4 Takeda Pharmaceutical Company
6.4.1 Takeda Pharmaceutical Company Corporation Information
6.4.2 Takeda Pharmaceutical Company Description and Business Overview
6.4.3 Takeda Pharmaceutical Company Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Takeda Pharmaceutical Company Primary Immunodeficiency Drug Product Portfolio
6.4.5 Takeda Pharmaceutical Company Recent Developments/Updates
6.5 Grifols Biologicals, Inc.
6.5.1 Grifols Biologicals, Inc. Corporation Information
6.5.2 Grifols Biologicals, Inc. Description and Business Overview
6.5.3 Grifols Biologicals, Inc. Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Grifols Biologicals, Inc. Primary Immunodeficiency Drug Product Portfolio
6.5.5 Grifols Biologicals, Inc. Recent Developments/Updates
6.6 Baxter
6.6.1 Baxter Corporation Information
6.6.2 Baxter Description and Business Overview
6.6.3 Baxter Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Baxter Primary Immunodeficiency Drug Product Portfolio
6.6.5 Baxter Recent Developments/Updates
6.7 Kedrion Biopharma
6.6.1 Kedrion Biopharma Corporation Information
6.6.2 Kedrion Biopharma Description and Business Overview
6.6.3 Kedrion Biopharma Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kedrion Biopharma Primary Immunodeficiency Drug Product Portfolio
6.7.5 Kedrion Biopharma Recent Developments/Updates
6.8 BPL Inc.
6.8.1 BPL Inc. Corporation Information
6.8.2 BPL Inc. Description and Business Overview
6.8.3 BPL Inc. Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 BPL Inc. Primary Immunodeficiency Drug Product Portfolio
6.8.5 BPL Inc. Recent Developments/Updates
6.9 Pharming Group
6.9.1 Pharming Group Corporation Information
6.9.2 Pharming Group Description and Business Overview
6.9.3 Pharming Group Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Pharming Group Primary Immunodeficiency Drug Product Portfolio
6.9.5 Pharming Group Recent Developments/Updates
6.10 Shire
6.10.1 Shire Corporation Information
6.10.2 Shire Description and Business Overview
6.10.3 Shire Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Shire Primary Immunodeficiency Drug Product Portfolio
6.10.5 Shire Recent Developments/Updates
6.11 Chengdu Rongsheng Pharmaceutical Co., Ltd
6.11.1 Chengdu Rongsheng Pharmaceutical Co., Ltd Corporation Information
6.11.2 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Description and Business Overview
6.11.3 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Product Portfolio
6.11.5 Chengdu Rongsheng Pharmaceutical Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Primary Immunodeficiency Drug Industry Chain Analysis
7.2 Primary Immunodeficiency Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Primary Immunodeficiency Drug Production Mode & Process
7.4 Primary Immunodeficiency Drug Sales and Marketing
7.4.1 Primary Immunodeficiency Drug Sales Channels
7.4.2 Primary Immunodeficiency Drug Distributors
7.5 Primary Immunodeficiency Drug Customers
8 Primary Immunodeficiency Drug Market Dynamics
8.1 Primary Immunodeficiency Drug Industry Trends
8.2 Primary Immunodeficiency Drug Market Drivers
8.3 Primary Immunodeficiency Drug Market Challenges
8.4 Primary Immunodeficiency Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global Primary Immunodeficiency Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Primary Immunodeficiency Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Primary Immunodeficiency Drug Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Primary Immunodeficiency Drug Sales (K Units) of Key Manufacturers (2019-2024)
    Table 5. Global Primary Immunodeficiency Drug Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Primary Immunodeficiency Drug Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Primary Immunodeficiency Drug Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Primary Immunodeficiency Drug Average Price (US$/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Primary Immunodeficiency Drug, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Primary Immunodeficiency Drug, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Primary Immunodeficiency Drug, Product Type & Application
    Table 12. Global Key Manufacturers of Primary Immunodeficiency Drug, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Primary Immunodeficiency Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Immunodeficiency Drug as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Primary Immunodeficiency Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Primary Immunodeficiency Drug Sales by Region (2019-2024) & (K Units)
    Table 18. Global Primary Immunodeficiency Drug Sales Market Share by Region (2019-2024)
    Table 19. Global Primary Immunodeficiency Drug Sales by Region (2025-2030) & (K Units)
    Table 20. Global Primary Immunodeficiency Drug Sales Market Share by Region (2025-2030)
    Table 21. Global Primary Immunodeficiency Drug Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Primary Immunodeficiency Drug Revenue Market Share by Region (2019-2024)
    Table 23. Global Primary Immunodeficiency Drug Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Primary Immunodeficiency Drug Revenue Market Share by Region (2025-2030)
    Table 25. North America Primary Immunodeficiency Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Primary Immunodeficiency Drug Sales by Country (2019-2024) & (K Units)
    Table 27. North America Primary Immunodeficiency Drug Sales by Country (2025-2030) & (K Units)
    Table 28. North America Primary Immunodeficiency Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Primary Immunodeficiency Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Primary Immunodeficiency Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Primary Immunodeficiency Drug Sales by Country (2019-2024) & (K Units)
    Table 32. Europe Primary Immunodeficiency Drug Sales by Country (2025-2030) & (K Units)
    Table 33. Europe Primary Immunodeficiency Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Primary Immunodeficiency Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Primary Immunodeficiency Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Primary Immunodeficiency Drug Sales by Region (2019-2024) & (K Units)
    Table 37. Asia Pacific Primary Immunodeficiency Drug Sales by Region (2025-2030) & (K Units)
    Table 38. Asia Pacific Primary Immunodeficiency Drug Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Primary Immunodeficiency Drug Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Primary Immunodeficiency Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Primary Immunodeficiency Drug Sales by Country (2019-2024) & (K Units)
    Table 42. Latin America Primary Immunodeficiency Drug Sales by Country (2025-2030) & (K Units)
    Table 43. Latin America Primary Immunodeficiency Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Primary Immunodeficiency Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Primary Immunodeficiency Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Primary Immunodeficiency Drug Sales by Country (2019-2024) & (K Units)
    Table 47. Middle East & Africa Primary Immunodeficiency Drug Sales by Country (2025-2030) & (K Units)
    Table 48. Middle East & Africa Primary Immunodeficiency Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Primary Immunodeficiency Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Primary Immunodeficiency Drug Sales (K Units) by Type (2019-2024)
    Table 51. Global Primary Immunodeficiency Drug Sales (K Units) by Type (2025-2030)
    Table 52. Global Primary Immunodeficiency Drug Sales Market Share by Type (2019-2024)
    Table 53. Global Primary Immunodeficiency Drug Sales Market Share by Type (2025-2030)
    Table 54. Global Primary Immunodeficiency Drug Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Primary Immunodeficiency Drug Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Primary Immunodeficiency Drug Revenue Market Share by Type (2019-2024)
    Table 57. Global Primary Immunodeficiency Drug Revenue Market Share by Type (2025-2030)
    Table 58. Global Primary Immunodeficiency Drug Price (US$/Unit) by Type (2019-2024)
    Table 59. Global Primary Immunodeficiency Drug Price (US$/Unit) by Type (2025-2030)
    Table 60. Global Primary Immunodeficiency Drug Sales (K Units) by Application (2019-2024)
    Table 61. Global Primary Immunodeficiency Drug Sales (K Units) by Application (2025-2030)
    Table 62. Global Primary Immunodeficiency Drug Sales Market Share by Application (2019-2024)
    Table 63. Global Primary Immunodeficiency Drug Sales Market Share by Application (2025-2030)
    Table 64. Global Primary Immunodeficiency Drug Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Primary Immunodeficiency Drug Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Primary Immunodeficiency Drug Revenue Market Share by Application (2019-2024)
    Table 67. Global Primary Immunodeficiency Drug Revenue Market Share by Application (2025-2030)
    Table 68. Global Primary Immunodeficiency Drug Price (US$/Unit) by Application (2019-2024)
    Table 69. Global Primary Immunodeficiency Drug Price (US$/Unit) by Application (2025-2030)
    Table 70. ADMA Biologics, Inc. Corporation Information
    Table 71. ADMA Biologics, Inc. Description and Business Overview
    Table 72. ADMA Biologics, Inc. Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 73. ADMA Biologics, Inc. Primary Immunodeficiency Drug Product
    Table 74. ADMA Biologics, Inc. Recent Developments/Updates
    Table 75. CSL Behring, LLC Corporation Information
    Table 76. CSL Behring, LLC Description and Business Overview
    Table 77. CSL Behring, LLC Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 78. CSL Behring, LLC Primary Immunodeficiency Drug Product
    Table 79. CSL Behring, LLC Recent Developments/Updates
    Table 80. Octapharma Corporation Information
    Table 81. Octapharma Description and Business Overview
    Table 82. Octapharma Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 83. Octapharma Primary Immunodeficiency Drug Product
    Table 84. Octapharma Recent Developments/Updates
    Table 85. Takeda Pharmaceutical Company Corporation Information
    Table 86. Takeda Pharmaceutical Company Description and Business Overview
    Table 87. Takeda Pharmaceutical Company Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 88. Takeda Pharmaceutical Company Primary Immunodeficiency Drug Product
    Table 89. Takeda Pharmaceutical Company Recent Developments/Updates
    Table 90. Grifols Biologicals, Inc. Corporation Information
    Table 91. Grifols Biologicals, Inc. Description and Business Overview
    Table 92. Grifols Biologicals, Inc. Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 93. Grifols Biologicals, Inc. Primary Immunodeficiency Drug Product
    Table 94. Grifols Biologicals, Inc. Recent Developments/Updates
    Table 95. Baxter Corporation Information
    Table 96. Baxter Description and Business Overview
    Table 97. Baxter Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 98. Baxter Primary Immunodeficiency Drug Product
    Table 99. Baxter Recent Developments/Updates
    Table 100. Kedrion Biopharma Corporation Information
    Table 101. Kedrion Biopharma Description and Business Overview
    Table 102. Kedrion Biopharma Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 103. Kedrion Biopharma Primary Immunodeficiency Drug Product
    Table 104. Kedrion Biopharma Recent Developments/Updates
    Table 105. BPL Inc. Corporation Information
    Table 106. BPL Inc. Description and Business Overview
    Table 107. BPL Inc. Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 108. BPL Inc. Primary Immunodeficiency Drug Product
    Table 109. BPL Inc. Recent Developments/Updates
    Table 110. Pharming Group Corporation Information
    Table 111. Pharming Group Description and Business Overview
    Table 112. Pharming Group Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 113. Pharming Group Primary Immunodeficiency Drug Product
    Table 114. Pharming Group Recent Developments/Updates
    Table 115. Shire Corporation Information
    Table 116. Shire Description and Business Overview
    Table 117. Shire Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 118. Shire Primary Immunodeficiency Drug Product
    Table 119. Shire Recent Developments/Updates
    Table 120. Chengdu Rongsheng Pharmaceutical Co., Ltd Corporation Information
    Table 121. Chengdu Rongsheng Pharmaceutical Co., Ltd Description and Business Overview
    Table 122. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 123. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Product
    Table 124. Chengdu Rongsheng Pharmaceutical Co., Ltd Recent Developments/Updates
    Table 125. Key Raw Materials Lists
    Table 126. Raw Materials Key Suppliers Lists
    Table 127. Primary Immunodeficiency Drug Distributors List
    Table 128. Primary Immunodeficiency Drug Customers List
    Table 129. Primary Immunodeficiency Drug Market Trends
    Table 130. Primary Immunodeficiency Drug Market Drivers
    Table 131. Primary Immunodeficiency Drug Market Challenges
    Table 132. Primary Immunodeficiency Drug Market Restraints
    Table 133. Research Programs/Design for This Report
    Table 134. Key Data Information from Secondary Sources
    Table 135. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Primary Immunodeficiency Drug
    Figure 2. Global Primary Immunodeficiency Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Primary Immunodeficiency Drug Market Share by Type in 2023 & 2030
    Figure 4. Immunoglobulin Product Picture
    Figure 5. Antibiotic Product Picture
    Figure 6. Stem Cell Product Picture
    Figure 7. Other Product Picture
    Figure 8. Global Primary Immunodeficiency Drug Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 9. Global Primary Immunodeficiency Drug Market Share by Application in 2023 & 2030
    Figure 10. Antibody Deficiency
    Figure 11. Cellular Immunodeficiency
    Figure 12. Innate Immune Disease
    Figure 13. Other
    Figure 14. Global Primary Immunodeficiency Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 15. Global Primary Immunodeficiency Drug Market Size (2019-2030) & (US$ Million)
    Figure 16. Global Primary Immunodeficiency Drug Sales (2019-2030) & (K Units)
    Figure 17. Global Primary Immunodeficiency Drug Average Price (US$/Unit) & (2019-2030)
    Figure 18. Primary Immunodeficiency Drug Report Years Considered
    Figure 19. Primary Immunodeficiency Drug Sales Share by Manufacturers in 2023
    Figure 20. Global Primary Immunodeficiency Drug Revenue Share by Manufacturers in 2023
    Figure 21. The Global 5 and 10 Largest Primary Immunodeficiency Drug Players: Market Share by Revenue in 2023
    Figure 22. Primary Immunodeficiency Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 23. Global Primary Immunodeficiency Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 24. North America Primary Immunodeficiency Drug Sales Market Share by Country (2019-2030)
    Figure 25. North America Primary Immunodeficiency Drug Revenue Market Share by Country (2019-2030)
    Figure 26. United States Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 27. Canada Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 28. Europe Primary Immunodeficiency Drug Sales Market Share by Country (2019-2030)
    Figure 29. Europe Primary Immunodeficiency Drug Revenue Market Share by Country (2019-2030)
    Figure 30. Germany Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. France Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. U.K. Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 33. Italy Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 34. Russia Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 35. Asia Pacific Primary Immunodeficiency Drug Sales Market Share by Region (2019-2030)
    Figure 36. Asia Pacific Primary Immunodeficiency Drug Revenue Market Share by Region (2019-2030)
    Figure 37. China Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. Japan Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. South Korea Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. India Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. Australia Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. China Taiwan Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Indonesia Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Thailand Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 45. Malaysia Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 46. Latin America Primary Immunodeficiency Drug Sales Market Share by Country (2019-2030)
    Figure 47. Latin America Primary Immunodeficiency Drug Revenue Market Share by Country (2019-2030)
    Figure 48. Mexico Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 49. Brazil Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 50. Argentina Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 51. Middle East & Africa Primary Immunodeficiency Drug Sales Market Share by Country (2019-2030)
    Figure 52. Middle East & Africa Primary Immunodeficiency Drug Revenue Market Share by Country (2019-2030)
    Figure 53. Turkey Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 54. Saudi Arabia Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 55. UAE Primary Immunodeficiency Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 56. Global Sales Market Share of Primary Immunodeficiency Drug by Type (2019-2030)
    Figure 57. Global Revenue Market Share of Primary Immunodeficiency Drug by Type (2019-2030)
    Figure 58. Global Primary Immunodeficiency Drug Price (US$/Unit) by Type (2019-2030)
    Figure 59. Global Sales Market Share of Primary Immunodeficiency Drug by Application (2019-2030)
    Figure 60. Global Revenue Market Share of Primary Immunodeficiency Drug by Application (2019-2030)
    Figure 61. Global Primary Immunodeficiency Drug Price (US$/Unit) by Application (2019-2030)
    Figure 62. Primary Immunodeficiency Drug Value Chain
    Figure 63. Primary Immunodeficiency Drug Production Process
    Figure 64. Channels of Distribution (Direct Vs Distribution)
    Figure 65. Distributors Profiles
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Irritable Bowel Syndrome Drug Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-4R15693
Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global Drugs for Treating Metabolic Disorders Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-1N16309
Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global Inflammatory Acne Drugs Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-19E18043
Tue Aug 27 00:00:00 UTC 2024

Add to Cart

Global Prefilled Insulin Injection Pens Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-38J15267
Tue Aug 27 00:00:00 UTC 2024

Add to Cart